Perinatal Vaccination by Transamniotic Fetal mRNA Delivery: Immunization Against Human Cytomegalovirus in a Rodent Model

被引:0
|
作者
Moskowitzova, Kamila
Naus, Abbie E.
Tsikis, Savas T.
Dang, Tanya T.
Lin, Shuqi B.
Zurakowski, David
Fauza, Dario O. [1 ]
机构
[1] Boston Childrens Hosp, Dept Surg, 300 Longwood Ave,Fegan 3, Boston, MA 02115 USA
关键词
Transamniotic mRNA therapy; Transamniotic fetal immunization; Fetal mRNA immunization; Transamniotic nucleic acid therapy; TRANAT; mRNA; Cytomegalovirus; INFECTION; EPIDEMIOLOGY; POTENT; VIRUS;
D O I
10.1016/j.jpedsurg.2024.161956
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Purpose: Gestational cytomegalovirus (CMV) infection is a prevalent disease with significant fetal and neonatal morbidity. MRNA vaccines have emerged as powerful options for postnatal immunization against infections. It has been shown that mRNA delivered into the amniotic fluid reaches the fetal circulation via the placenta. We investigated whether transamniotic mRNA delivery could be a viable strategy for perinatal CMV immunization, first utilizing a rodent model. Methods: Pregnant Sprague Dawley dams underwent volume-matched intra-amniotic injections in all their fetuses (n = 103) of either human CMV (hCMV) envelope glycoprotein B (hCMV-gB) antigen mRNA encapsulated in lipopolyplex (mRNA group; n = 56), or of the same lipopolyplex without mRNA (controls; n = 47) on gestational day 17 (E17; term = E21-22). Term placentas were screened for host production of hCMV-gB by protein immunoblotting. Serum hCMV-gB IgG antibodies were measured at term, and 7 (P7) and 14 (P14) days after birth by ELISA. Results: Overall fetal/neonatal survival was 86% (89/103). Immunoblotting showed hCMV-gB presence in term mRNA placentas (p = 0.008 vs. controls). No hCMV-gB IgG was detected in the serum of term fetuses (4 days following transamniotic delivery). However, significantly increased serum hCMV-gB IgG levels were present in mRNA pups at P7 (p = 0.008) and P14 (p = 0.006) when controlled by mRNA-free injections (11-19 days after transamniotic administration). Conclusions: Transamniotic fetal mRNA delivery of a human cytomegalovirus antigen can induce a humoral immune response extending into the neonatal period in a healthy rat model. Fetal mRNA vaccination via the minimally invasive transamniotic route may become a practical strategy for the prevention of perinatal infections. Level of Evidence: N/A (animal and laboratory study). Type of Study: Animal and Laboratory Study. (c) 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页数:5
相关论文
共 11 条
  • [1] Transamniotic Delivery of Surfactant Protein B mRNA in a Healthy Model
    Moskowitzova, Kamila
    Naus, Abbie E.
    Dang, Tanya T.
    Zurakowski, David
    Fauza, Dario O.
    FETAL DIAGNOSIS AND THERAPY, 2025, 52 (02) : 148 - 154
  • [2] Vaccination against the human cytomegalovirus
    Plotkin, Stanley A.
    Boppana, Suresh B.
    VACCINE, 2019, 37 (50) : 7437 - 7442
  • [3] Optimization of DNA immunization against human cytomegalovirus
    Endrész, V
    Burián, K
    Berencsi, K
    Gyulai, Z
    Kari, L
    Horton, H
    Virok, D
    Méric, C
    Plotkin, SA
    Gönczöl, E
    VACCINE, 2001, 19 (28-29) : 3972 - 3980
  • [4] A Quadrivalent mRNA Immunization Elicits Potent Immune Responses against Multiple Orthopoxviral Antigens and Neutralization of Monkeypox Virus in Rodent Models
    Su, Caixia
    Li, Sha
    Wen, Yang
    Geng, Xiya
    Yin, Quanyi
    Wang, Yun
    Xiong, Yelin
    Liu, Zhihua
    VACCINES, 2024, 12 (04)
  • [5] Transcutaneous immunization with lipid offers a new route of vaccination against Helicobacter pylori and a new candidate delivery vehicle
    Chambers, Mark Andrew
    EXPERT REVIEW OF VACCINES, 2010, 9 (03) : 249 - 253
  • [6] Design and Analysis of Rhesus Cytomegalovirus IL-10 Mutants as a Model for Novel Vaccines against Human Cytomegalovirus
    Logsdon, Naomi J.
    Eberhardt, Meghan K.
    Allen, Christopher E.
    Barry, Peter A.
    Walter, Mark R.
    PLOS ONE, 2011, 6 (11):
  • [7] Expression of an RNase P ribozyme against the mRNA encoding human cytomegalovirus protease inhibits viral capsid protein processing and growth
    Trang, P
    Kim, K
    Zhu, JM
    Liu, FY
    JOURNAL OF MOLECULAR BIOLOGY, 2003, 328 (05) : 1123 - 1135
  • [8] Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization
    Nelson, Cody S.
    Jenks, Jennifer A.
    Pardi, Norbert
    Goodwin, Matthew
    Roark, Hunter
    Edwards, Whitney
    McLellan, Jason S.
    Pollara, Justin
    Weissman, Drew
    Permar, Sallie R.
    JOURNAL OF VIROLOGY, 2020, 94 (09)
  • [9] Skin Vaccination against Cervical Cancer Associated Human Papillomavirus with a Novel Micro-Projection Array in a Mouse Model
    Corbett, Holly J.
    Fernando, Germain J. P.
    Chen, Xianfeng
    Frazer, Ian H.
    Kendall, Mark A. F.
    PLOS ONE, 2010, 5 (10):
  • [10] Vaccination with a Human Papillomavirus L2 Multimer Provides Broad Protection against 17 Human Papillomavirus Types in the Mouse Cervicovaginal Challenge Model
    Han, Zhenwei
    Wang, Shen
    Mu, Ting
    Zhao, Ping
    Song, Lingli
    Zhang, Ying
    Zhao, Jin
    Yin, Wen
    Wu, Yue
    Wang, Huan
    Gong, Bo
    Ji, Min
    Roden, Richard B. S.
    Yang, Yanping
    Klein, Michel
    Wu, Ke
    VACCINES, 2024, 12 (06)